Publications
The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer
Debio 1562M, a 2nd Generation ADC Targeting CD37, Shows High Potency Against AML and MDS and Safe Toxicological Profile for…
Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123
Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release
The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model
Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin
Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal…
Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors